Since Huggins and Hodges demonstrated the androgen responsiveness of human cancer in 1941, 1 androgen ablation has remained the standard therapy for patients with advanced prostate cancer. Once tumor growth is androgen- independent, the median survival of patients is less than one year and no agent has yet been shown to improve the survival of such patients. The transitions from androgen dependence to androgen independence represents a critical juncture in the progression of prostate cancer. The Program Project;s unifying hypothesis is that aberrant androgen receptor activation causing androgen receptor-regulated gene expression in association with dysregulation of anti-apoptotic genes promotes the transition from androgen dependent to androgen-independent prostate cancer. Three hypotheses will be tested: . The transition to androgen independence is mediated by an alteration of androgen receptor function. Androgen receptor function may be altered a point mutation, CAG repeat deletion, splice variant, change in protein stability or phosphorylation and/or gene amplification. Mutations in the androgen receptor gene change the steroid binding specificity of the receptor and enhance its response to adrenal androgens. Both wild-type and functionally active mutant androgen receptors contribute to the growth of androgen-independent prostate cancer through ligand-independent mechanisms of activation. Androgen receptor regulated gene products promote the emergence of androgen-independent growth of prostate cancer cells that survive the withdrawal of testicular androgens. . Altered expression or function of protooncogenes and survival genes promotes the emergence of androgen-independence by enabling androgen responsive cancer cells to survive androgen deprivation. . Micro-environmentally-mediated epigenetic changes in gene expression support the transition from androgen dependence to androgen independence through heightened sensitive to growth stimulation by microenvironmental factors or androgen receptor mediated mechanisms. Project 1 identifies and characterizes mutations in the androgen receptor. Project 2 determines the role of androgen receptor activation and androgen regulated genes in androgen-independent prostate cancer. Project 3 examines protooncogenes/survival genes that enhance survival and growth potential of androgen-independent cells. Project 4 examines the microenvironmental effects on expression of genes involves in growth regulation. An Immunoanalysis Core will support each Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA077739-01
Application #
2604782
Study Section
Subcommittee G - Education (NCI)
Program Officer
Freeman, Colette S
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Fiandalo, Michael V; Wilton, John H; Mantione, Krystin M et al. (2018) Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate 78:213-221
Askew, Emily B; Bai, Suxia; Parris, Amanda B et al. (2017) Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11. Mol Cell Endocrinol 443:42-51
Komisarof, Justin; McCall, Matthew; Newman, Laurel et al. (2017) A four gene signature predictive of recurrent prostate cancer. Oncotarget 8:3430-3440
Su, Shifeng; Chen, Xiaoyu; Geng, Jiang et al. (2017) Melanoma antigen-A11 regulates substrate-specificity of Skp2-mediated protein degradation. Mol Cell Endocrinol 439:1-9
Itkonen, Harri M; Brown, Michael; Urbanucci, Alfonso et al. (2017) Lipid degradation promotes prostate cancer cell survival. Oncotarget 8:38264-38275
Stocking, John J; Fiandalo, Michael V; Pop, Elena A et al. (2016) Characterization of Prostate Cancer in a Functional Eunuch. J Natl Compr Canc Netw 14:1054-60
Frasinyuk, Mykhaylo S; Mrug, Galyna P; Bondarenko, Svitlana P et al. (2016) Antineoplastic Isoflavonoids Derived from Intermediate ortho-Quinone Methides Generated from Mannich Bases. ChemMedChem 11:600-11
Minges, John T; Grossman, Gail; Zhang, Ping et al. (2015) Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor. J Biol Chem 290:25174-87
Montecinos, Viviana P; Morales, Claudio H; Fischer, Thomas H et al. (2015) Selective targeting of bioengineered platelets to prostate cancer vasculature: new paradigm for therapeutic modalities. J Cell Mol Med 19:1530-7

Showing the most recent 10 out of 103 publications